Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.60 |
| ▸ | CTSS | P25774 | 3/20 | 0.60 |
| ▸ | CTSK | P43235 | 3/20 | 0.60 |
| ▸ | CTSH | P09668 | 1/20 | 0.60 |
| ▸ | CXCL8 | P10145 | 7/20 | 0.59 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | MC5R | P33032 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | MC1R | Q01726 | 1/20 | 0.54 |
| ▸ | NPY1R | P25929 | 1/20 | 0.54 |
| ▸ | NPY2R | P49146 | 1/20 | 0.54 |
| ▸ | NPY4R | P50391 | 1/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.53 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30974438 | 0.89 | CXCR4 (0.58) | CTSLCTSSCTSKCTSHCXCR4 | |
| SCHEMBL29392562 | 0.86 | CXCL8 (0.64) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL30567818 | 0.86 | KISS1R (0.58) | CXCR4KISS1R | |
| SCHEMBL1307858 | 0.86 | KISS1R (0.58) | CXCR4KISS1R | |
| SCHEMBL30519048 | 0.86 | KISS1R (0.60) | CTSLCTSSCTSKCTSHCXCL8 | |
| SCHEMBL31688340 | 0.86 | KEAP1 (0.64) | CXCR4KEAP1NPY1RNPY2RNPY4R | |
| Hydrochloric Acid SCHEMBL11644315 | 0.86 | KISS1R (0.57) | CXCR4KISS1R | |
| SCHEMBL29942444 | 0.84 | KISS1R (0.56) | CXCR4KISS1R | |
| SCHEMBL11593491 | 0.84 | KISS1R (0.56) | CXCR4KISS1R | |
| SCHEMBL32679440 | 0.84 | CXCR4 (0.65) | CTSLCTSSCTSKCTSHCXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260131028-A1 | COMBINATION CANCER THERAPY | DELTA NEXT GENE LLC (US) | 2026-05-14 | — | — | US | claimed |
| WO-2023196620-A1 | COMBINATION CANCER THERAPY | Delta Next-Gene, LLC (US) | 2023-10-12 | — | — | WO | claimed |
| US-11325958-B2 | Cyclin G1 inhibitors and related methods of treating cancer | Delta Next-Gene, LLC (US) | 2022-05-10 | — | — | US | claimed |
| US-20260131028-A1 | COMBINATION CANCER THERAPY | DELTA NEXT GENE LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12173041-B2 | Cyclin G1 inhibitors and related methods of treating cancer | Delta Next-Gene, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2023196620-A1 | COMBINATION CANCER THERAPY | Delta Next-Gene, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20220380802-A1 | CYCLIN G1 INHIBITORS AND RELATED METHODS OF TREATING CANCER | Delta Next-Gene, LLC | 2022-12-01 | — | — | US | disclosed |
| US-11325958-B2 | Cyclin G1 inhibitors and related methods of treating cancer | Delta Next-Gene, LLC (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131028-A1 | COMBINATION CANCER THERAPY | CDKL1, CCNL2, CDKL2 | CTSL 9/4885CTSS 42/4885CTSK 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.